Novavax to Participate in Fireside Chat at the 2021 Cantor Virtual Global Healthcare Conference
Novavax, Inc. (Nasdaq: NVAX) announced its participation in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 29, 2021, from 8:40 – 9:10 a.m. EDT. The discussion will feature the company's COVID-19 vaccine candidate, NVX-CoV2373. Key participants include Gregory M. Glenn, M.D., and John J. Trizzino. A replay of the session will be available on the company's website for 90 days. Novavax is advancing its developing vaccines, including NanoFlu™, which is set for regulatory submission.
- None.
- None.
GAITHERSBURG, Md., Sept. 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.
Fireside chat details: | |||
Date: | Wednesday, September 29, 2021 | ||
Time: | 8:40 – 9:10 a.m. Eastern Daylight Time (EDT) | ||
Moderator: | Charles C. Duncan, Ph.D. | ||
Novavax participants: | Gregory M. Glenn, M.D., President, Research and Development and John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer | ||
A replay of the recorded fireside session will be available through the events page of the Company's website at ir.novavax.com for 90 days.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Contacts:
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com
Solebury Trout
Alexandra Roy | 617-221-9197
aroy@soleburytrout.com
Media
Alison Chartan | 240-720-7804
Laura Keenan | 202-709-7521
media@novavax.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-fireside-chat-at-the-2021-cantor-virtual-global-healthcare-conference-301383813.html
SOURCE Novavax, Inc.
FAQ
What is the date of Novavax's fireside chat at the 2021 Cantor Virtual Global Healthcare Conference?
What time will Novavax's fireside chat take place?
Who will participate in the Novavax fireside chat?
What vaccine candidate will be discussed at the Novavax fireside chat?
How long will the replay of the Novavax fireside chat be available?
